Presyncope Unmasking a Massive Upper Gastrointestinal (GI) Bleed One Month After Multivessel Percutaneous Coronary

Dalal A Obaid1, Khawla Y Alawadhi2, Khalid Haiba3

  • 1Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, ARE.

Cureus
|December 22, 2025
PubMed

Upper gastrointestinal (GI) bleeding is a life-threatening emergency that requires timely recognition, resuscitation, and carefully tailored transfusion strategies. Dual antiplatelet therapy (DAPT), while essential after percutaneous coronary intervention (PCI), substantially increases bleeding risk and creates a major therapeutic dilemma when severe bleeding occurs soon after stent placement. We report an 87-year-old man with hypertension, dyslipidemia, and ischemic heart disease who presented with presyncope and dizziness one month after multivessel PCI with four drug-eluting stents. He was on DAPT with aspirin and clopidogrel. Laboratory evaluation revealed severe anemia (hemoglobin (Hb) 5.3 g/dL), and he subsequently developed hematemesis and melena with hemodynamic compromise. Urgent endoscopy identified multiple large esophageal ulcers with active bleeding, which were successfully managed with adrenaline injection. Transfusion was guided by a restrictive strategy, targeting Hb 8-9 g/dL in view of his recent cardiac history. A multidisciplinary decision was made to de-escalate antiplatelet therapy to clopidogrel monotherapy while continuing high-dose proton pump inhibitor therapy. This case underscores the complexity of balancing thrombosis and bleeding risks in the immediate post-PCI period, highlighting the role of multidisciplinary coordination, restrictive transfusion thresholds, and timely endoscopic intervention.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
337
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
203
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
324
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
197
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
700